此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Optimized Cardiopulmonary Bypass Flow Strategy Based on Ideal Body Weight in Obese Patients Undergoing Cardiac Surgery (IDEALFLOW)

2026年10月29日 更新者:Centre Hospitalier Universitaire, Amiens

Cardiopulmonary bypass (CPB) pump flow is typically calculated according to body surface area (BSA) derived from actual body weight and temperature, following the 2024 European guidelines recommending an indexed flow of 2.4 L/min/m². However, in obese patients, using actual weight leads to a high BSA and thus elevated pump flow, increasing technical challenges such as the need for larger cannulas, higher circulating blood volume, and elevated pump speeds. These adjustments may increase risks of hemodilution, transfusion, and hemolysis. Given that lean body mass in obese patients is similar to that of non-obese patients of the same height-and that aerobic metabolism depends on lean mass-adjusting CPB flow based on ideal body weight rather than actual weight could reduce transfusions and associated complications. Several observational studies support the concept of using ideal body weight for CPB flow calculation in obese patients. Despite this, no randomized controlled trial has yet addressed the clinical impact of this approach. Given the increasing prevalence of obesity and the practical challenges it poses during cardiac surgery, a controlled clinical trial is warranted.

The investigators hypothesize that adjusting the cardiopulmonary bypass (CPB) flow according to the ideal body weight rather than the actual body weight in obese patients could reduce the need for blood transfusions and limit the associated complications.

研究概览

研究类型

介入性

注册 (估计的)

184

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients aged over 18 years
  • Patients with obesity (BMI > 30 kg/m²)
  • Scheduled cardiac surgery under cardiopulmonary bypass (CPB):
  • Coronary artery bypass grafting (CABG)
  • Aortic valve replacement
  • Mitral valve repair or replacement
  • Surgery on the aortic root (aortic tube, Bentall procedure, Tirone David, or others)
  • Combined surgery
  • Affiliation to a social security scheme
  • Written informed consent

Exclusion Criteria:

  • Minors
  • BMI < 30 kg/m²
  • Off-pump cardiac surgery
  • Surgery on the aortic arch
  • Planned perioperative hypothermia < 32ºC
  • Emergency surgery
  • Heart transplantation or mechanical circulatory support surgery
  • Infectious endocarditis
  • Participation in another clinical trial within the past 30 days
  • Pregnant, parturient, or breastfeeding women
  • Patients under guardianship, curatorship, or deprived of civil rights
  • Advanced chronic kidney disease (renal clearance < 30 ml/min)
  • Coexisting disease with a high probability of death within 6 months
  • Preoperative anemia (hemoglobin < 10 g/dL)
  • Body surface area (actual body weight) > 2.5 m²

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:body surface area (BSA) calculated from ideal body weight

Cardiac surgery under cardiopulmonary bypass (CPB) with CPB flow indexed at 2.4 ml/min/m², using body surface area (BSA) calculated from ideal body weight (Lorentz formula)

CPB is standardized according to the following protocol:

  • Cardiac index at 2.4 ml/min/m²
  • Mean arterial pressure during CPB between 50 and 80 mm Hg
  • Central venous oxygen saturation > 65%
  • Hematocrit > 25%
  • DO₂ > 280 ml/min/m²
  • VCO₂/DO₂ > 6 (VCO₂: CO₂ production) CPB will be performed under normothermia, with a temperature > 36°C.

Anticoagulation will be managed according to center practices to maintain an activated clotting time (ACT) > 400 seconds, in accordance with recommendations.

有源比较器:BSA calculated from actual body weight.

Cardiac surgery under CPB with CPB flow indexed at 2.4 ml/min/m², using BSA calculated from actual body weight.

CPB is standardized according to the following protocol:

  • Cardiac index at 2.4 ml/min/m²
  • Mean arterial pressure during CPB between 50 and 80 mm Hg
  • Central venous oxygen saturation > 65%
  • Hematocrit > 25%
  • DO₂ > 280 ml/min/m²
  • VCO₂/DO₂ > 6 (VCO₂: CO₂ production) CPB will be performed under normothermia, with a temperature > 36°C.

Anticoagulation will be managed according to center practices to maintain an activated clotting time (ACT) > 400 seconds, in accordance with recommendations.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
reduction in the incidence of erythrocyte concentrates transfused
大体时间:1 day

reduction in the incidence of erythrocyte concentrates transfused from the start to the end of cardiopulmonary bypass (CPB)

1 day

次要结果测量

结果测量
措施说明
大体时间
hematocrit measurement during CPB
大体时间:1 day

Hemodilution quantified by hematocrit measurement during CPB

1 day
Number of platelet concentrates administered during CPB
大体时间:1 day

Number of platelet concentrates administered during CPB

1 day
Number of fresh frozen plasma units administered during CPB
大体时间:1 day

Number of fresh frozen plasma units administered during CPB

1 day
Number of labile blood products administered during the entire ICU stay
大体时间:1 day

Number of labile blood products administered during the entire ICU stay

1 day
Number of Acute kidney injury
大体时间:within 7 days

Acute kidney injury defined according to KDIGO criteria by an increase in serum creatinine ≥26.5 μmol/L or at least 1.5 times the baseline value within 7 days after surgery compared to the preoperative baseline

within 7 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月21日

初级完成 (估计的)

2029年9月1日

研究完成 (估计的)

2029年9月1日

研究注册日期

首次提交

2026年10月29日

首先提交符合 QC 标准的

2026年10月29日

首次发布 (实际的)

2026年11月4日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年10月29日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • PI2026_843_0111

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅